BREAKING NEWS!! UNIBEN Don Finds Cure For HIV/AIDS

BREAKING NEWS!! UNIBEN Don Finds Cure For HIV/AIDS

 

After two years of rigorous work, history is being made here in Nigeria:

Prof. Isaiah Ibeh of the University of Benin, on Tuesday announced the development of a new drug that can ‘cure’ HIV and AIDS. Ibeh, who is the Dean of the School of Basic Medical Sciences of the university, confirmed to reporters in Benin that the drug had undergone “series of successful tests”. 

According to him, research on the project was started in 2010 and culminated in the development of “Deconcotion X (DX)–Liquid or Bioclean 11 for the cure of HIV and AIDS”. “The existing retroviral drugs are intervention drugs for the management of AIDS but our new discovery is a possible cure," he assured.

Prof Ibeh said, "We are at the threshold of making history, in the sense that we seem to have with us something that will permanently take care of what over time seems to have defied all solutions. We are talking about the latest discovery of an oral drug made from plants extraction in Nigeria for the possible cure of the pandemic HIV and AIDS virus.

“We have tried to look at the product first; its toxicological analysis and discovered that it has a large safety margin. “This means that if animals or human beings are exposed to it, they will not suffer any serious harm at all from the exposure. “It also helped us to know the quantity we can conveniently give to animals and will feel secure that nothing untoward will happen.

“We have also done the bacteriological analysis on it, after which we looked at its effect on the virus and the result was quite revealing and refreshing.” 

Ibeh also said that the drug had been exposed to series of medical examination both in Nigeria and in the USA. He added that the drug had performed well on patients with the HIV virus and had shown evidence of total restoration of damaged tissues.

“The result showed an increase in the body weight of the individual administered with DX. The body weight was statistically significant when compared with the control group.”

He said that further tests were being conducted to determine “at what point will a patient become negative after being administered the drug?”.

“This verification is necessary because it is what is used to measure whether infection is still there or not. So we need to know the siro-convention time. But preliminary results showed that of the five latest patients orally administered with the drugs, our findings is that up to seven months, three of them were siro negative while two were sill faintly positive." 

Prof Ibeh is appealling for support from the Federal Government and relevant bodies to assist the university with equipment and other resources to sustain the research.